It rose to fame after it was approved based on a small study showing it appeared to help symptoms of patients reporting to the hospital with acute heart failure symptoms.
Some explicit criticism also came from Wall Street, where analysts were quick to dismiss the study for several reasons, including flaws such as a failure to evaluate the potential impact of label changes on reporting.